Second Quarter 2026
Filed Aug 12, 2026Private Placement Eliminates Balance Sheet Overhang and Alleviates Previously Disclosed Going Concern Doubt
Cash increased following the private placement and net sales rose on government grant revenue, while operating expenses declined. The company nevertheless reported a net loss, with other expense rising due to derivative fair-value losses, deferred offering-cost write-offs and interest expense.
Key metrics
as reported| Metric | Value | q/q | y/y |
|---|---|---|---|
| Net salesGAAP | $124,914 | – | increased by $120,914 |
| Cost of goods soldGAAP | - | – | – |
| Operating expensesGAAP | 1,492,251 | – | decreased by $296,546 |
| Loss from continuing operationsGAAP | $1.4 million | – | – |
| Total other expenseGAAP | (1,519,419 ) | – | increased by $1,192,684 |
| Net lossGAAP | $ (2,886,756 ) | – | – |
| Net loss per basic shareGAAP | $0.35 per basic share | – | – |
| Cash and cash equivalentsGAAP | $27.7 million | – | – |
2026 outlook
- NoteCommercial availability of the PEAK Series is expected in 2026.
- NoteSolidion expects to make the pouch cell commercially available in Q2 2026.
What drove it
- Net sales increased primarily because of government grant revenue recognized during the period.
- Operating expenses declined primarily due to lower general and administrative costs, including reduced personnel and professional services expenses.
- Operating expenses also declined due to lower research and development costs, including personnel expenses associated with commercialization of battery cell products and third-party validation testing of the proprietary silicon anode.
- Other expense was driven by a $917,780 loss from the change in fair value of derivative liabilities related to the Forward Purchase Agreement and warrants related to the March private placement financing.
- Other expense included a $549,915 non-cash write-off of deferred offering costs associated with a registration statement withdrawn in June 2026 and $153,597 of interest expense primarily related to short-term notes.
Concerns
- The Company reported a net loss of $ (2,886,756 ).
- Total other expense rose to (1,519,419 ) from (326,735 ).
- The Company disclosed a non-cash loss of $0.9 million related to change in fair value of derivatives.
- Commercial availability of the PEAK Series and the pouch cell remains forward-looking.
What to watch
- Progress toward commercial availability of the PEAK Series in 2026 and early integration and testing with select data center partners.
- Updates on commercialization of the high-power 9.5Ah pouch cell for industrial and military drone applications.
- Use of private-placement proceeds to accelerate commercialization of Extreme-Climate Battery technology, fulfill customer demand, expand inventory, advance prototype development and support working capital.
- Whether government grants and deliveries of proprietary silicon anode products continue to support net sales.
Balance sheet and cash flow
- $27.7 million in cash and cash equivalents at June 30, 2026, compared to $0.2 million at December 31, 2025.
- The private placement generated $35 million in gross proceeds and closed on June 9, 2026.
- The Company completed a restructuring of its August 2024 equity financing, eliminating all Series C and D Pre-Funded Warrants and the corresponding derivative liability.
Analysis
Solidion reported net sales of $124,914 for the three months ended June 30, 2026, compared with $4,000 for the three months ended June 30, 2025. The company attributed the increase primarily to government grant revenue recognized during the period. The release also cited delivery of proprietary silicon anode products as a source of revenue.
Cost discipline improved within the operating expense line. Operating expenses were 1,492,251, compared with 1,788,797 in the prior-year period, a decrease of $296,546. Management attributed the reduction to lower general and administrative costs, including personnel and professional services expenses, as well as decreased research and development costs tied to battery-cell commercialization activities and third-party validation testing.
Profitability remained negative. The company reported a loss from continuing operations of $1.4 million and a net loss of $ (2,886,756 ), or $0.35 per basic share. Total other expense was (1,519,419 ), compared with (326,735 ) in the prior-year period, reflecting a $917,780 derivative-liability fair-value loss, a $549,915 non-cash write-off of deferred offering costs and $153,597 of interest expense.
Liquidity was the principal change in the period. Cash and cash equivalents were $27.7 million at June 30, 2026, compared with $0.2 million at December 31, 2025. The company said its private placement generated $35 million in gross proceeds, and that completion of the financing alleviated the substantial doubt about its ability to continue as a going concern that had previously been disclosed. It also restructured its August 2024 equity financing to eliminate Series C and D Pre-Funded Warrants and the related derivative liability.
Commercial execution is now central to the outlook described in the release. Solidion expects to make its pouch cell commercially available in Q2 2026 and expects commercial availability of its PEAK Series in 2026. The release identifies early integration and testing with select data center partners, commercialization of Extreme-Climate Battery technology and fulfillment of customer demand as intended uses and milestones for the new financing.
Management, verbatim
Solidion’s much improved balance sheet reflects the commitment of long term shareholders and reaffirms the strategy of building an organization that can compete revenue wise,
Jaymes Winters, Chief Executive Officer of Solidion Technology
Not in the filing
stated, not guessed- Gross profit and gross margin
- Operating income or loss reported as a financial-statement line item
- Non-GAAP gross profit, operating income, net income or EPS
- Diluted EPS and prior-year EPS comparisons
- Prior-quarter comparisons for reported operating metrics
- Segment revenue, segment profitability and segment comparisons
- Operating cash flow
- Free cash flow
- Capital expenditures
- Debt balances
- Share repurchases
- Dividends
- Financial revenue guidance
- Gross-margin guidance
- Operating-expense guidance
- Tax-rate guidance
- Previous-release outlook for comparison with actual results
AlphAI analysis generated from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure was cross-checked against the filing text; consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.